FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to cardiology, and concerns diagnosing various forms of the left ventricular hypertrophy. That is ensured by determining an amount of a necrosis marker - cardiac troponin T, cardiac function marker - NT-proBNP and one of an inflammation marker - GDF-15. Comparing their amounts to the reference values enables diagnosing a physiological or pathological left ventricular hypertrophy. Besides, the presence of the pathological hypertrophy requires determining the relation between the cardiac function marker and inflammatory marker, as well as between the necrosis marker and inflammatory marker, and comparing these relations to the reference enables stating if the individual suffers from hypertrophic nonobstructive cardiomyopathy, or hypertrophic obstructive cardiomyopathy, or hypertrophy accompanying pressure overload.
EFFECT: improving the diagnostic procedure.
7 cl, 3 tbl, 3 ex
